# Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

> **NCT07040098** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 228 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)

## Interventions

- **DRUG:** Sintilimab
- **RADIATION:** Short-course radiotherapy
- **RADIATION:** Long-course concurrent chemoradiotherapy
- **COMBINATION_PRODUCT:** CAPOX

## Key facts

- **NCT ID:** NCT07040098
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07040098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07040098, "Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07040098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*